West Pharmaceutical Services Inc filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-06-01. Between them they name 2 people, with 1 appointment and 2 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: Eric M. Green, Chief Executive Officer
On March 9, 2026, West Pharmaceutical Services, Inc. (the "Company") filed a Current Report on Form 8-K announcing that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the "Board") of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth transition.
Departing: Eric M. Green, Director
As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.
Appointed: Michel Lagarde, President and Chief Executive Officer
Pursuant to the Employment Agreement, Mr. Lagarde will serve as President and Chief Executive Officer of the Company, will be appointed as a member of the Board as of the Start Date, and will be recommended for election as a member of the Board at future shareholder meetings as long as he is President and Chief Executive Officer.
Find people with the same kind of experience as the Chief Executive Officer at West Pharmaceutical Services Inc, with the record behind each one.
Find candidates like Chief Executive Officer at West Pharmaceutical Services IncNew leaders review vendors and budgets in their first months. Get an alert the next time West Pharmaceutical Services Inc is in the news or changes leadership.
Get an alert when West Pharmaceutical Services Inc changes leadershipTools for this story
Each opens in a new tab, filled in for West Pharmaceutical Services Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.